Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | F2 | P00734 | 5/20 | 0.62 |
| ▸ | DTYMK | P23919 | 4/20 | 0.56 |
| ▸ | TERT | O14746 | 2/20 | 0.55 |
| ▸ | P2RY2 | P41231 | 2/20 | 0.49 |
| ▸ | P2RY4 | P51582 | 2/20 | 0.49 |
| ▸ | P2RY6 | Q15077 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.48 |
| ▸ | RNASEL | Q05823 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29420169 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL30369215 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29376343 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29386416 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29376007 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29624082 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29959424 | 1.00 | F2 (0.62) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL30656494 | 0.99 | F2 (0.61) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29354146 | 0.98 | F2 (0.60) | F2DTYMKTERTP2RY2P2RY4 | |
| SCHEMBL29361881 | 0.98 | F2 (0.60) | F2DTYMKTERTP2RY2P2RY4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 440 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2026090160-A2 | CD4-TARGETED IL-15 MOLECULES AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2026-04-30 | — | — | WO | claimed |
| EP-4701663-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | Insilico Medicine IP Limited (HK) | 2026-03-04 | — | — | EP | claimed |
| EP-4554628-A1 | HIV IMMUNOGENIC POLYPEPTIDES AND VACCINES AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2025-05-21 | — | — | EP | claimed |
| WO-2024222890-A1 | PROLYL HYDROXYLASE DOMAIN-CONTAINING PROTEIN (PHD) INHIBITORS, COMBINATIONS AND USES THEREOF | INSILICO MEDICINE IP LIMITED (CN) | 2024-10-31 | — | — | WO | claimed |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA INC (US) | 2024-06-27 | — | — | US | claimed |
| EP-4326329-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | Civi Biopharma, Inc. (US) | 2024-02-28 | — | — | EP | claimed |
| WO-2024015741-A1 | HIV IMMUNOGENIC POLYPEPTIDES AND VACCINES AND USES THEREOF | GILEAD SCIENCES, INC. (US) | 2024-01-18 | — | — | WO | claimed |
| EP-4204092-A1 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2023-07-05 | — | — | EP | claimed |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-12-01 | — | — | US | claimed |
| WO-2022226217-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | CIVI BIOPHARMA, INC. (US) | 2022-10-27 | — | — | WO | claimed |
| EP-3999107-A1 | HIV VACCINES AND METHODS OF MAKING AND USING | GILEAD SCIENCES, INC. (US) | 2022-05-25 | — | — | EP | claimed |
| WO-2022046644-A1 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-03-03 | — | — | WO | claimed |
| EP-4029868-B1 | MCL-1 INHIBITORS | GILEAD SCIENCES INC (US) | 2026-05-20 | — | — | EP | disclosed |
| CN-122055369-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| CN-122055373-A | Bridged tricyclic carbamoyl pyridone compounds and uses thereof | 吉利德科学公司 | 2026-05-15 | — | — | CN | disclosed |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | GILEAD SCIENCES INC (US) | 2026-05-14 | — | — | US | disclosed |
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | GILEAD SCIENCES, INC. | 2022-03-10 | — | — | US | disclosed |
| WO-2022046644-A1 | MULTI-SPECIFIC ANTIGEN BINDING MOLECULES TARGETING HIV AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 2022-03-03 | — | — | WO | disclosed |
| US-20220049021-A1 | FLT3L-Fc FUSION PROTEINS AND METHODS OF USE | GILEAD SCIENCES, INC. | 2022-02-17 | — | — | US | disclosed |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | GILEAD SCIENCES, INC. (US) | 2022-02-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220073473-A1 | TOLL LIKE RECEPTOR MODULATOR COMPOUNDS | TLR8, TLR3, TLR6 | F2 4608/4885DTYMK 1307/4885TERT 4237/4885 |
| US-20240207409-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885DTYMK 437/4885TERT 3199/4885 |
| US-20260130893-A1 | PRMT5 INHIBITORS AND USES THEREOF | PRMT5, PRMT1, PRMT6 | F2 4873/4885DTYMK 1296/4885TERT 216/4885 |
| US-20220380761-A1 | ORAL DELIVERY OF OLIGONUCLEOTIDES | RNGTT, RNMT, SRRT | F2 4885/4885DTYMK 437/4885TERT 3199/4885 |
| US-11236085-B2 | PD-1/PD-L1 inhibitors | PDCD1, CD274, PDCD1LG2 | F2 3949/4885DTYMK 561/4885TERT 242/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.